Drugs / H3B-6527
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03424577 | Dec 2017 → Jan 2018 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02834780 | Dec 2016 → Feb 2022 | hepatocellular carcinoma | H3 Biomedicine Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H3B-6527 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02834780 ↗ |
| Action | Inhibit | “a covalent inhibitor of the fibroblast growth factor receptor (FGFR) 4” PMID 30368584 ↗ Oct 2018 |
| Modality | Small molecule | — CHEMBL3939295 ↗ |
| Route | Oral | “H3B-6527 by mouth once or twice daily at specified doses.” NCT02834780 ↗ |